Product
ADG126-ADG106
1 clinical trial
1 indication
Indication
Advanced/Metastatic Solid TumorsClinical trial
A First-in-Human (FIH), Open-Label, Phase 1/2 Dose Escalation and Expansion Study of ADG126, ADG126 in Combination With Anti PD1 Antibody, and ADG126 in Combination With ADG106 in Patients With Advanced/Metastatic Solid TumorsStatus: Recruiting, Estimated PCD: 2024-03-31